Background: Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease. Since current treatments are unsatisfactory for many patients, there is a high need for effective drugs for this debilitating disease. Recent pathogenic insights suggest inflammasome activation and IL-1β production are important in HS. Colchicine is efficacious in the IL-1β- and inflammasome-mediated diseases gout, familial Mediterranean fever and Behçet's disease, and therefore a potentially effective drug in HS. Objective: To investigate the efficacy of colchicine in HS. Methods: In an open prospective pilot study, 8 HS patients were treated with the accepted gout maintenance regimen of 0.5 mg colchicine b.i.d. orally up to 4 months. Efficacy was assessed by a physician global assessment. Results: Colchicine treatment did not result in a clinically relevant improvement of disease severity. Three patients experienced nausea and diarrhea as known side effects. Conclusion: Colchicine in the used dose regimen does not ameliorate HS severity. Copyright

Additional Metadata
Keywords Acne inversa, Behçet's disease, Familial Mediterranean fever, Gout, Hidradenitis suppurativa treatment, Inflammasome
Persistent URL,
Journal Dermatology: international journal for clinical and investigative dermatology
van der Zee, H.H, & Prens, E.P. (2011). The anti-inflammatory drug colchicine lacks efficacy in hidradenitis suppurativa. Dermatology: international journal for clinical and investigative dermatology, 223(2), 169–173. doi:10.1159/000332846